New drug ARO-CFB targets kidney disease in early trial
NCT ID NCT06209177
First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 22 times
Summary
This early-stage trial tested a new drug called ARO-CFB in 49 healthy volunteers and people with IgA nephropathy, a kidney disease. The goal was to check if the drug is safe and how the body processes it. Participants received either one or two doses of the drug or a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Auckland, 1010, New Zealand
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARO-CFB
What this could lead to
If successful, this could point toward a new treatment option for IgA nephropathy by targeting the complement system to control kidney disease.
What could go wrong
This is an early phase 1/2a trial with only 49 participants, so safety and effectiveness are not yet proven. The drug may not work or could have unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.